Poised For Growth

With strong brands that have already established themselves in the market, the company has now declared intentions for massive capital investments and output expansion.

- 

The Piramal Group has interests in a variety of industries, including financial services (Piramal Enterprises), real estate (Piramal Realty) and pharmaceuticals (Piramal Pharma). The Group's revenue is expected to be around USD 1.9 billion in FY 2022 with operations in 30 countries and brand recognition in more than 100 markets. 

Piramal Pharma provides a range of unique products and services through end-to-end production capabilities spanning 15 global facilities and a distribution network in more than 100 countries. It has a three-tier quality governance approach, and facilities in the Piramal network have cleared 1,130 customer audits, 169 regulatory audits, and 36 USFDA inspections since January 2011. 

Piramal Pharma comprises three business verticals: Piramal Critical Care (PCC), a complex hospital generics business;

Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; and the India Consumer Healthcare business, which sells over-the-counter goods. 

The major business units of Piramal Pharma Solutions include drug discovery, pharmaceutical development, manufacturing, antibody drug conjugation, generic APIs, and nutrition solutions. The Consumer Product segment is one of the fastest-growing players in the domestic consumer healthcare market. Among the well-known brands produced by the company are Lacto Calamine, Saridon, Polycrol, i-know, and Little's baby care line. 

There is a joint venture between Piramal Pharma and Allergan. With the successful launch of a variety of cutting-edge medications and devices for conditions like glaucoma, dry eye, infections, and inflammations, the speciality pharmaceutical company Allergan India has become the market leader in the

quickly expanding ophthalmic sector.